The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
"Aptamer has successfully developed the required Optimers and demonstrated their performance through in-house assays. After being shipped to Unilever, the Optimers delivered highly positive and reproducible results in their laboratories, indicating their potential for use in downstream products. In parallel, Aptamer has streamlined the Optimers to improve their function and manufacturability and is working to transfer these to Unilever for further evaluation," it explained.
Based on this, Aptamer and Unilever are now drafting patent applications to protect these developments and downstream commercial applications.
Just growth from here, hopefully back to the 20’s plus before you know it
DYOR
I agree Indie,
It's never nice seeing a share that's 98% down over the year.
But these RNS's are starting to build something and the current market cap is starting to look very low for the potential here.
Good luck all.
Feel for those really underwater. Recent TR1’s are all encouraging so hang on in there.
This sector has been sold off generally, but the potential remains, and I see Aptamar as having some serious potential.
What investors/speculators should remember is that these little Biopharmas can offer tremendous returns, yes, we are aware of the risks, but the potentially huge rewards are part of the allure, as well as investing in a company that will potentially benefit the lives of many.
When a Company is making significant progress with a major, it should be noticed, not just Unilever, who we know about, but also todays major pharmaceutical Company, that hasn’t been named yet.
Longer term investors may recall Novacyt, in this sector, whose share price languished at 6p in November 2019.
By October 2020 it was around £12.00.
So, to the poster that bought at 25p, yes, irritating to be sitting on a paper loss, but there can be some very serious upside.
I think that is unfair. All AIM STOCKS are small companies and that is what you are investing in. FTSE 100 perhaps would suit you better? Bio like exploration companies need to raise money in order to progess. I am sorry that you bought in at a higher rate, if you have held them then with Unilever on board hopefully it wont be long until you see a return 🤞
What a joke. Many of us bought in well above 25. I mean, well done if you bought in at the recent lows buy I would be cautious about keeping any money here long term. Hoping in 20 years or so I might get my money back. It's a phenomenal concept but this company has suckered in shareholders.
£0.8 million of deals were signed in December 2023 contributing to a signed deals pipeline today of £1.3 million, which are at various stages of being progressed through the laboratory to recognise as revenue.
@Mozax
Company has about 8 weeks of cash runway left
I will get excited when they actually confirm a deal that brings cash in before they run out.
Otherwise it’s yet again another SH call for cash
Jam levels high - actual delivery low
Well, when Petro turns up telling us about ‘the baby’ one might assume the general public is picking this up.
What usually happens is that a big ‘riser’ gets picked up on the boards then all the comedians turn up with their Un- researched opinions.
The upside is that The Company gets noticed, and other investors are able to look into the investment case in its totality.
Wow! The potential here with Unilever on board is yes as you say truly astounding and I do think the market has completely overlooked that ...
Porky, todays news has relevance, but look deeper into the Company.
How this has fallen from 120p when it’s in bed with Unilever is simply astounding.
A teeny Aim Company partnering on a patent of its science with a £100 Billion Global Goliath.
Wait until word gets out.
Pump news prior to placing - good luck
Mention of others deals in market is not relevant imo. It’s designed to try and excite with potential jam
News they need to put out is we have received x cash in the bank for a signed contract, not what might be.
NT to buy, even teeny amounts.
Only a matter of time before we get that major deal imo.
Looks like the climb is on
GLAH
This is a HUGE market..
Targeted delivery to specific cell populations is showing increasing use across the pharmaceutical sector, as it holds the potential for increased efficacy and reduced side effects from medications. Exemplar publicised partnerships for specifically targeted precision medicine developments include Ionis Pharmaceuticals Inc. licensing a single delivery vehicle from Bicycle Therapeutics Inc. for $45 million upfront, with additional milestone payments and royalties for each program developed under the collaboration; Partnering of Takeda Pharmaceutical with Peptidream Inc, with Peptidream Inc receiving up to $3.5 billion excluding royalty payments for delivery vehicles targeting the central nervous system. Both these deals demonstrate the urgent requirement and high values associated with developments and assets of this nature in the sector for successful targeting delivery vehicles.
This Company has been completely overlooked by the market, and to see the SP fall to this level from 120p is astonishing.
The market is very fearful of costs, cash flow, equity placings etc to the point that almost no value is being attributed to the underlying fundamentals.
A partnership with Unilever! Working on patenting Aptamars product together, a teeny AIM Company partnering with a Global Super Major. Wow.
I looked into the Shareholder base.
I only discovered Apta myself last week as I hold a tiny Pharma working in the same sphere, I’ve now bought 1.5M shares mostly this morning, and will continue adding, what a dream price.
All in the ISA.
Am I concerned about a potential fund raise? No, this is on the Cusp of growing significantly.
And looking at todays price action, the market is starting to notice too.
With a MCap of £3m it is unlikely institutional investors would come in unless a VCT takes an interest. The company have a lot to do to convince investors after the shockingly discounted fund raise last year (78% discount). With fixed expense base of only £3.5m it is really peanuts for a company with so much potential. Surely there is a cornerstone investor who would put in £2m or more to get them through 2024.
Yes actual revenue numbers and a clear timescale to reach break even are critical. Some are worried that we will be hit with another discounted placement. Director purchases would show more confidence that they believe in what they are achieving.
Too true LTB ...There is so much value added potential locked away within Aptamer's sp....as Warren Buffet advises.....buy when the market is fearful....and in Apts case the fear is clearly manageable.
And let's also remember that similar validations are taking place since January from the Top5 Pharma (for another product); and sometime in calendar 2024 (as per Co Presentations in March), the Neuro-Bio lateral flow test will go into development.
Once the penny drops and institutional investors finally understand Aptimers true potential and cease fretting about various short term "what ifs" planted and raked around by a few short term speculators the sp will revalue....and I'm convinced it will rise...DYOR.
No numbers announced, but Apta still receives fee-for services, it's not doing this for free; plus, more contracts flow from such successful development, both from this Top15 pharma and also similar pharmas. IMO
In any case, this is good publicity for APTA, likely to bring more business in.
“A significant effect was seen from the Optimer-delivered gene therapy… probability of these results is more than 99% due to the Optimer delivery of the gene therapy.”
Results look very promising and some really nice comparisons with other companies too. A great RNS showing potentially a very lucrative future. But they do need to bring in some revs pretty soon to extend the current runway, so currently not without risk.
Angel Investor. .